natgillin/translations-raw huggingface dataset:
Twenty-four percent of children (11/46) treated for 24 weeks and 40 % of children (19/48) treated for 48 weeks had a &gt; 15 percentile height-for-age decrease from pre-treatment to the end of 5 year long-term follow-up compared to pre-treatment baseline percentiles.
Dvadeset četiri posto djece (11/46) liječene tijekom 24 tjedna i 40% djece (19/48) liječene tijekom 48 tjedana imalo je smanjenje &gt; 15 percentila visine za određenu dob u razdoblju prije početka liječenja do završetka petogodišnjeg kontrolnog razdoblja u usporedbi s percentilima na početku ispitivanja prije liječenja.
Twenty-four percent of patients met at least one of the following three criteria at baseline for scoring severity: body temperature &gt; 38.5°C, leukocyte count &gt; 15,000, or creatinine value ≥1.5 mg/dl.
Na početku ispitivanja, 24% bolesnika zadovoljilo je najmanje jedan od sljedeća tri kriterija za bodovanje težine bolesti: tjelesna temperatura &gt; 38,5°C, broj leukocita &gt; 15 000 ili vrijednost kreatinina ≥1,5 mg/dl.
Twenty-four percent of subjects (11/46) treated for 24 weeks and 40 % of subjects (19/48) treated for 48 weeks had a &gt; 15 percentile height-for-age decrease from pre-treatment to the end of the 5 year long-term follow-up compared to pre-treatment baseline percentile.
U 24% djece (11/46) liječene 24 tjedna i 40% djece (19/48) liječene 48 tjedana zabilježen je pad za &gt; 15 percentila na percentilnoj krivulji rasta za dob od razdoblja prije početka liječenja do kraja 5-godišnjeg dugotrajnog praćenja u usporedbi s percentilima prije početka liječenja.
Twenty-one of these patients (1%) experienced a QTcF &gt; 500 msec.
U 21 bolesnika ( &lt; 1%) zabilježen je QTcF &gt; 500 msek.
Twenty-one patients (1%) experienced a QTcF &gt; 500 msec (see section 4.4).
Dvadeset jedan (1%) bolesnik imao je QTcF &gt; 500 msek (vidjeti dio 4.4).
Twenty-two of 25 (88%) patients with haematologic complete remission also had minimal residual disease (MRD) responses (defined as MRD by PCR &lt; 1 x 10-4).
Dvadeset i dva od 25 (88%) bolesnika s hematološki potpunom remisijom također je imalo odgovor na minimalnu rezidualnu bolest (MRB) (definiran kao MRB po PCR &lt; 1 x 10-4).
Two (2/957, 0.2%) of these tolvaptan treated-patients, as well as a third patient from an extension open label trial, exhibited increases in hepatic enzymes ( &gt; 3xULN) with concomitant elevations in BT ( &gt; 2xULN).
Od tih bolesnika liječenih tolvaptanom u njih dvojice (2/957; 0,2%), kao i u još jednog, trećeg, bolesnika iz produžetka otvorenog ispitivanja, došlo je do porasta jetrenih enzima ( &gt; 3 x GGN) uz istovremen porast ukupnog bilirubina ( &gt; 2 x GGN).
Two cases of hyperglycaemia-related emergencies (diabetic ketoacidosis and diabetic hyperglycaemic coma) were reported following a dose increase of pasireotide to 60 mg in medical treatment naïve patients; one in a patient with untreated hyperglycaemia and HbA1c &gt; 8% prior to initiation of pasireotide and the other in a patient with untreated hyperglycaemia and a fasting plasma glucose of 359 mg/dl, respectively.
Dva slučaja hitnih stanja povezanih s hiperglikemijom (dijabetička ketoacidoza i dijabetička hiperglikemijska koma) prijavljena su nakon povećanja doze pasireotida na 60 mg u bolesnika bez prethodne terapije lijekovima; jedan u bolesnika s neliječenom hiperglikemijom i HbA1c &gt; 8% prije uvođenja pasireotida, a drugi u bolesnika s neliječenom hiperglikemijom i glukozom u plazmi natašte od 359 mg/dl.
Two minor metabolites were detected following administration of an oral dose of [14C] alogliptin, N-demethylated alogliptin, M-I ( &lt; 1% of the parent compound), and N-acetylated alogliptin, M-II ( &lt; 6% of the parent compound).
Nakon primjene peroralne doze [14C] alogliptina nađena su dva minorna metabolita, N-demetilirani alogliptin, M-I ( &lt; 1% izvornog spoja) i N-acetilirani alogliptin, M-II ( &lt; 6% izvornog spoja).
Two minor metabolites were detected following administration of an oral dose of [14C] alogliptin, N-demethylated alogliptin, M-I ( &lt; 1% of the parent compound), and N-acetylated alogliptin, M-II ( &lt; 6% of the parent compound).
Nakon primjene peroralne doze [14C] alogliptina pronađena su dva minorna metabolita, N-demetilirani alogliptin, M-I ( &lt; 1% izvornog spoja) i N-acetilirani alogliptin, M-II ( &lt; 6% izvornog spoja).
Two multi-center, open-label, cross-over, uncontrolled, randomized studies in previously treated adults/adolescents with severe haemophilia A ( &lt; 1%) and one multicenter, open label, uncontrolled study in previously treated children &lt; 12 years with severe haemophilia A were conducted.
Provedena su dva multicentrična, otvorena, ukrižena, nekontrolirana, randomizirana ispitivanja u prethodno liječenih odraslih osoba/adolescenata s teškom hemofilijom A ( &lt; 1%) i jedno multicentrično, otvoreno, nekontrolirano ispitivanje u prethodno liječene djece &lt; 12 godina s teškom hemofilijom A.
Two multi-centre, open-label, cross-over, uncontrolled, randomized studies in previously treated adults/adolescents with severe haemophilia A ( &lt; 1%) and one multicentre, open label, uncontrolled study in previously treated children &lt; 12 years with severe haemophilia A were conducted.
Provedena su dva multicentrična otvorena, ukrižena, nekontrolirana, randomizirana ispitivanja u prethodno liječenih odraslih osoba/adolescenata s teškom hemofilijom A ( &lt; 1%) i jedno multicentrično, otvoreno nekontrolirano ispitivanje u prethodno liječene djece &lt; 12 godina s teškom hemofilijom A.
Two multi-centre, open-label, cross-over, uncontrolled, randomized studies in previously treated adults/adolescents with severe haemophilia A ( &lt; 1%) and one multicentre, open label, uncontrolled study in previously treated children &lt; 12 years with severe haemophilia A were conducted.
Provedena su dva multicentrična otvorena, ukrižena, nekontrolirana, randomizirana ispitivanja u prethodno liječenih odraslih osoba/adolescenata s teškom hemofilijom A ( &lt; 1%) i jedno multicentrično, otvoreno, nekontrolirano ispitivanje u prethodno liječene djece &lt; 12 godina s teškom hemofilijom A.
Two non-conjugated metabolites (XL184-N-oxide and XL184 amide cleavage product), which possess &lt; 1% of the on-target kinase inhibition potency of parent cabozantinib, each represent &lt; 10% of total drug-related plasma exposure.
Dva nekonjugirana metabolita (XL184-N-oksid i XL184 produkt cijepanja amida), koji posjeduju &lt; 1% sposobnost inhibicije ciljne kinaze ishodišnog kabozantiniba, pri čemu svaki predstavlja &lt; 10% ukupne ekspozicije vezane za lijek u plazmi.
Two non-conjugated metabolites (XL184-N-oxide and XL184 amide cleavage product), which possess &lt; 1% of the on-target kinase inhibition potency of parent cabozantinib, each represent &lt; 10% of total drug-related plasma exposure.
Svaki od dva nekonjugirana metabolita (XL184-N-oksid i XL184 produkt razgradnje amida), koja posjeduju &lt; 1 % potentnosti ishodišnog kabozantiniba za inhibiciju ciljne kinaze, predstavlja &lt; 10 % ukupne plazmatske izloženosti lijeku.
Two of the 14 untreated subjects participating in the clothing-to-skin contact regimen had measurable oxybutynin plasma concentrations (Cmax &lt; 0.1 ng/ml) during the 48 hours following contact with treated subjects; oxybutynin was not detectable with the remaining 12 untreated subjects.
Dva od 14 neliječenih ispitanika koji su podvrgnuti režimu kontakta odjeće s kožom imali su mjerljive koncentracije oksibutinina u plazmi (Cmax &lt; 0,1 ng/ml) tijekom 48 sati nakon kontakta s liječenim ispitanicima; oksibutinin nije otkriven u preostalih 12 neliječenih ispitanika.
Two of these patients had a QTcB Grade 3 increase ( &gt; 500 msec) that was also an increase &gt; 60 msec from baseline.
Dvoje od tih bolesnika imalo je povećanje QTcB 3. stupnja ( &gt; 500 ms) koje je ujedno bilo i povećanje &gt; 60 ms od početne vrijednosti.
Two patients ( &lt; 1%) who received sunitinib were diagnosed with congestive heart failure (CHF).
U dva bolesnika ( &lt; 1%) koji su primali sunitinib dijagnosticirano je kongestivno zatajenje srca.
Two patients had HIV virologic failure defined as confirmed HIV-1 RNA ≥ 200 copies/ml after previous &lt; 50 copies/ml; these failures occurred 36 and 48 weeks after end of simeprevir treatment.
Dva bolesnika imala su HIV virološki neuspjeh definiran kao potvrđena HIV-1 RNK ≥ 200 kopija/ml nakon prethodne &lt; 50 kopija/ml; ovaj neuspjeh se pojavio 36 i 48 tjedana nakon kraja liječenja simeprevirom.
Two patients, one on placebo and one on ivacaftor permanently discontinued treatment for elevated transaminases, each &gt; 8 x ULN.
Dva bolesnika, jedan koji je primao placebo i jedan liječen ivakaftorom, trajno su prekinula liječenje zbog povišenih transaminaza za &gt; 8 puta GGN.
Two patients, one on placebo and one on ivacaftor, permanently discontinued treatment for elevated transaminases, each &gt; 8 x ULN.
Dva bolesnika, jedan koji je primao placebo i jedan liječen ivakaftorom, trajno su prekinula liječenje zbog povišenih transaminaza za &gt; 8 puta GGN.
Two primary regulators of mTORC1 signalling are the oncogene suppressors tuberin-sclerosis complexes 1 &amp; 2 (TSC1, TSC2).
Dva glavna regulatora signalnih putova mTORC1 su onkogeni supresori kompleksi tuberozne skleroze 1 &amp; 2 (TSC1, TSC2).
Tyverb-induced diarrhoea is usually low- grade, with severe diarrhoea of NCI CTCAE grades 3 and 4 occurring in &lt; 10% and &lt; 1% of patients, respectively.
Proljev izazvan lijekom Tyverb najčešće je niskog stupnja, dok se teški proljev 3. ili 4. stupnja prema NCI CTCAE pojavljuje u &lt; 10%, odnosno &lt; 1% bolesnika.
UAB Merck Sharp &amp; Dohme Tel.: +370 5 278 02 47 msd_lietuva@merck.com
UAB Merck Sharp &amp; Dohme Tel.: +378 5 278 02 47 msd_lietuva@merck.com
UAB “JOHNSON &amp; JOHNSON” filiāle Latvijā Tel: +371 6789 3561
Janssen-Cilag Polska Sp. z o.o. filiāle Latvijā Tel: +371 6789 3561
ubacute bacterial endocarditis severe renal impairment (GFR &lt; 30 ml/min) and in dialysis-dependent patients
ubakutnim bakterijskim endokarditisom teškim oštećenjem bubrega (GFR &lt; 30 ml/min) i u bolesnika ovisnih o dijalizi.
UK (England &amp; Wales)1 (2006)
Ujedinjeno Kraljevstvo (Engleska i Wales)1 (2006)
Ulipristal acetate is highly bound ( &gt; 98%) to plasma proteins, including albumin, alpha-l-acid glycoprotein, and high density lipoprotein.
Ulipristalacetat se u visokom postotku ( &gt; 98%) veže na proteine plazme, uključujući albumin, alfa-1- kiseli glikoprotein i lipoprotein velike gustoće.
Ulipristal acetate is highly bound ( &gt; 98%) to plasma proteins, including albumin, alpha-l-acid glycoprotein, high density lipoprotein and low density lipoprotein.
Ulipristalacetat se znatno veže ( &gt; 98%) na proteine plazme, uključujući albumin, alfa-1-kiseli glikoprotein te na lipoproteine visoke i niske gustoće.
Ultibro Breezhaler demonstrated a statistically superior improvement versus tiotropium in the percentage of “days able to perform usual daily activities” over 26 weeks (8.45%, p &lt; 0.001).
Ultibro Breezhaler pokazao je statistički značajno poboljšanje u odnosu na tiotropij u postotku „dana kada mogu obavljati uobičajene svakodnevne aktivnosti“ tijekom 26 tjedana (8,45%, p &lt; 0,001).
Ultibro Breezhaler increased post-dose FEV1 AUC0-12 (primary endpoint) by 140 ml at 26 weeks (p &lt; 0.001) compared to fluticasone/salmeterol.
Ultibro Breezhaler povećao je FEV1 AUC0-12 nakon doze (primarni ishod) za 140 ml u 26 tjedana (p &lt; 0,001) u usporedbi s flutikazonom/salmeterolom.
Ultibro Breezhaler increased post-dose trough FEV1 by 200 ml compared to placebo at the 26-week primary endpoint (p &lt; 0.001) and showed statistically significant increases compared to each monotherapy component treatment arm (indacaterol and glycopyrronium) as well as the tiotropium treatment arm, as shown in the below table.
Ultibro Breezhaler je povećao najniži FEV1 nakon doze za 200 ml u usporedbi s placebom u primarnom ishodu u 26 tjednu (p &lt; 0,001) i pokazao statistički značajno povećanje u usporedbi sa svakom terapijskom skupinom koja je primala monoterapiju jednom od komponenti (indakaterolom i glikopironijem), kao i u terapijskoj skupini koja je primala tiotropij, kako je prikazano u tablici u nastavku.
Ulunar Breezhaler demonstrated a statistically superior improvement versus tiotropium in the percentage of “days able to perform usual daily activities” over 26 weeks (8.45%, p &lt; 0.001).
Ulunar Breezhaler pokazao je statistički značajno poboljšanje u odnosu na tiotropij u postotku „dana kada mogu obavljati uobičajene svakodnevne aktivnosti“ tijekom 26 tjedana (8,45%, p &lt; 0,001).
Ulunar Breezhaler increased post-dose FEV1 AUC0-12 (primary endpoint) by 140 ml at 26 weeks (p &lt; 0.001) compared to fluticasone/salmeterol.
Ulunar Breezhaler povećao je FEV1 AUC0-12 nakon doze (primarni ishod) za 140 ml u 26 tjedana (p &lt; 0,001) u usporedbi s flutikazonom/salmeterolom.
Ulunar Breezhaler increased post-dose trough FEV1 by 200 ml compared to placebo at the 26-week primary endpoint (p &lt; 0.001) and showed statistically significant increases compared to each monotherapy component treatment arm (indacaterol and glycopyrronium) as well as the tiotropium treatment arm, as shown in the below table.
Ulunar Breezhaler je povećao najniži FEV1 nakon doze za 200 ml u usporedbi s placebom u primarnom ishodu u 26 tjednu (p &lt; 0,001) i pokazao statistički značajno povećanje u usporedbi sa svakom terapijskom skupinom koja je primala monoterapiju jednom od komponenti (indakaterolom i glikopironijem), kao i u terapijskoj skupini koja je primala tiotropij, kako je prikazano u tablici u nastavku.
Unchanged ponatinib accounted for 24% and &lt; 1% of the administered dose in faeces and urine, respectively, with the remainder of the dose comprising metabolites.
Nepromijenjeni ponatinib predstavlja 24% i manje od 1% primijenjene doze u fecesu odnosno u mokraći s preostalom doza koju sačinjavaju metaboliti.
Unchanged thalidomide was a minor component ( &lt; 3% of the dose) in urine.
Nepromijenjeni talidomid bio je manja komponenta ( &lt; 3% doze) u mokraći.
uncommon ( &gt; 1/1,000, &lt; 1/100): cardiac arrest, mitral valve incompetence, pericardial effusion, venous thrombosis, cardiac tamponade, myocardial rupture rare ( &gt; 1/10,000, &lt; 1/1,000): pulmonary embolism
manje često ( &gt; 1/1 000 i &lt; 1/100): zastoj srca, insuficijencija mitralne valvule perikardijalni izljev, tromboza vena, tamponada srca, ruptura miokarda rijetko ( &gt; 1/10 000 i &lt; 1/1 000): plućna embolija
uncommon ( &gt; 1/1,000, &lt; 1/100): cardiac arrest, mitral valve incompetence, pericardial effusion, venous thrombosis, cardiac tamponade, myocardial rupture rare ( &gt; 1/10,000, &lt; 1/1,000): pulmonary embolism
manje često ( &gt; 1/1 000 i &lt; 1/100): zastoj srca, insuficijencija mitralne valvulve, perikardijalni izljev, tromboza vena, tamponada srca, ruptura miokarda rijetko ( &gt; 1/10 000 i &lt; 1/1000): plućna embolija
Uncommon (≥ 1/1,000 &lt; 1/100)
Manje često (≥ 1/1000 &lt; 1/100)
Uncommon (≥ 1/1,000 to &lt; 1/100)
Manje često (≥ 1/1000 do &lt; 1/100)
Uncommon (≥ 1/1,000 to &lt; 1/100)
Manje često (≥ 1/1000 i &lt; 1/100)
Uncommon (≥ 1/1,000 to &lt; 1/100)
Manje često (≥1/1000 i &lt; 1/100)
uncommon (≥ 1/1,000 to &lt; 1/100) rare (≥ 1/10,000 to &lt; 1/1,000) very rare ( &lt; 1/10,000) not known (cannot be estimated from the available data)
manje često (≥ 1/1000 do &lt; 1/100) rijetko (≥ 1/10 000 do &lt; 1/1000) vrlo rijetko ( &lt; 1/10,000) nepoznato (ne može se procijeniti iz dostupnih podataka)
uncommon (≥ 1/1,000 to &lt; 1/100) rare (≥ 1/10,000 to &lt; 1/1,000) very rare ( &lt; 1/10,000) not known (cannot be estimated from the available data)
manje često: (≥ 1/1000 do &lt; 1/100) rijetko: (≥ 1/10 000 do &lt; 1/1000) vrlo rijetko ( &lt; 1/10,000) nepoznato (ne može se procijeniti iz dostupnih podataka)
uncommon (≥ 1/1,000 to &lt; 1/100) rare (≥ 1/10,000 to &lt; 1/1,000) very rare ( &lt; 1/10,000) not known (cannot be estimated from the available data)
često: (≥ 1/100 i &lt; 1/10) manje često: (≥ 1/1000 i &lt; 1/100) rijetko: (≥ 1/10 000 i &lt; 1/1000) nepoznato: (ne može se procijeniti iz dostupnih podataka)
Uncommon (≥ 1/1,000 to &lt; 1/100) Rare (≥ 1/10,000 to &lt; 1/1,000) Very rare ( &lt; 1/10,000)
često (≥ 1/100 i &lt; 1/10) manje često (≥ 1/1000 i &lt; 1/100) rijetko (≥ 1/10 000 i &lt; 1/1000) vrlo rijetko (≥ 1/10 000)
Uncommon (≥ 1/1,000 to &lt; 1/100) Rare (≥ 1/10,000 to &lt; 1/1,000) Very rare ( &lt; 1/10,000).
Manje često (≥ 1/1000 i &lt; 1/100) Rijetko (≥ 1/10 000 i &lt; 1/1000) Vrlo rijetko ( &lt; 1/10 000)
Uncommon (≥ 1/1,000 to &lt; 1/100): Hypoventilation.
Manje često (≥ 1/1000 i &lt; 1/100): hipoventilacija
Uncommon (≥ 1/1,000 to &lt; 1/100): Sinus pause.
Manje često (≥ 1/1000 i &lt; 1/100): sinusna pauza
Uncommon (≥ 1/1,000 to &lt; 1/100); Rare (≥ 1/10,000 to &lt; 1/1,000);
Manje često (≥ 1/1000 do &lt; 1/100) Rijetko (≥ 1/10 000 do &lt; 1/1000)
Uncommon (≥ 1/1,000, &lt; 1/100)
Manje često (≥ 1/1000, &lt; 1/100)
Uncommon (≥ 1/1,000, &lt; 1/100) Not known
Manje često (≥ 1/1000, &lt; 1/100) Nepoznato
Uncommon (≥ 1/1000 to &lt; 1/100)
Manje često (≥ 1/1000 i &lt; 1/100)
Uncommon (≥1/1,000 and &lt; 1/100) Rare (≥1/10,000 and &lt; 1/1000) Very rare ( &lt; 1/10,000)
manje često (≥ 1/1000 i &lt; 1/100) rijetko (≥ 1/10 000 i &lt; 1/1000) vrlo rijetko ( &lt; 1/10 000) nepoznato (učestalost se ne može procijeniti iz dostupnih podataka)
Uncommon (≥1/1,000 to &lt; 1/100)
Manje često (≥ 1/1000 i &lt; 1/100)
Uncommon (≥1/1,000 to &lt; 1/100) pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after G-CSF administration.
Prijavljene su manje česte (≥ 1/1000 i &lt; 1/100) plućne nuspojave, posebice intersticijska upala pluća, nakon primjene faktora stimulacije rasta granulocita (G-CSF).
Uncommon (≥1/1,000 to &lt; 1/100) Rare (≥1/10,000 to &lt; 1/1,000)
Manje često (≥1/1000 i &lt; 1/100) Rijetko (≥1/10 000 i &lt; 1/1000)
Uncommon (≥1/1,000 to &lt; 1/100)
Manje često (≥1/1000 do &lt; 1/100)
Uncommon (≥1/1,000 to &lt; 1/100)
Manje često (≥1/1000 i &lt; 1/100)
Uncommon (≥1/1,000 to &lt; 1/100)
Rijetko (≥1/10 000 i &lt; 1/1000)
Uncommon (≥1/1,000 to &lt; 1/100)
Često (≥1/100 do &lt; 1/10)
Uncommon (≥1/1,000 to &lt; 1/100) Rare (≥1/10,000 to &lt; 1/1,000) Very rare ( &lt; 1/10,000)
Manje često (≥1/1 000 i &lt; 1/100) Rijetko (≥1/10 000 i &lt; 1/1 000) Vrlo rijetko ( &lt; 1/10 000)
Uncommon (≥1/1,000 to &lt; 1/100) Rare (≥1/10,000 to &lt; 1/1,000) Very rare ( &lt; 1/10,000)
Manje često (≥1/1000 do &lt; 1/100) Rijetko (≥1/10 000 do &lt; 1/1000) Vrlo rijetko ( &lt; 1/10 000)
Uncommon (≥1/1,000 to &lt; 1/100) Rare (≥1/10,000 to &lt; 1/1,000) Very rare ( &lt; 1/10,000)
Manje često (≥1/1000 i &lt; 1/100) Rijetko (≥1/10 000 i &lt; 1/1000) Vrlo rijetko ( &lt; 1/10 000)
Uncommon ( 0.1% to &lt; 1%) reports of fistulae that involve areas of the body other than the gastrointestinal tract (e.g. bronchopleural and biliary fistulae) were observed across various indications.
U ispitivanjima u raznim indikacijama manje često ( 0,1% i &lt; 1%) su prijavljene fistule u dijelovima tijela izvan gastrointestinalnog trakta (npr. bronhopleuralne i bilijarne fistule).
Uncommon ( 1/1,000 to &lt; 1/100)
Manje često (1/1000 i &lt; 1/100)
Uncommon ( 1/1,000 to &lt; 1/100) Rare ( 1/10,000 to &lt; 1/1,000) Very rare ( &lt; 1/10,000)
Manje često ( 1/1000 i &lt; 1/100) Rijetko (1/10 000 i &lt; 1/1000) Vrlo rijetko ( &lt; 1/10 000)
Uncommon (1/1,000 to &lt; 1/100)
Manje često (≥1/1000 i &lt; 1/100)
Uncommon (1/1,000 to &lt; 1/100)
Manje često (1/1000 do &lt; 1/100)
Uncommon (1/1,000 to &lt; 1/100)
Manje često (1/1000 i 1/100)
Uncommon (1/1,000 to &lt; 1/100)
često (≥ 1/100 i &lt; 1/10)
Uncommon (1/1,000 to &lt; 1/100) Rare (1/10,000 to &lt; 1/1,000) Very rare ( &lt; 1/10,000)
Manje često (≥ 1/1000 do &lt; 1/100) Rijetko (≥ 1/10 000 do &lt; 1/1000) Vrlo rijetko ( &lt; 1/10 000)
Uncommon (1/1,000 to &lt; 1/100) Rare (1/10,000 to &lt; 1/1,000) Very rare ( &lt; 1/10,000)
Manje često (≥ 1/1000 i &lt; 1/100) Rijetko (≥ 1/10 000 i &lt; 1/1000) Vrlo rijetko ( &lt; 1/10 000)
Uncommon (1/1,000 to &lt; 1/100) Rare (1/10,000 to &lt; 1/1,000) Very rare ( &lt; 1/10,000)
Manje često (1/1000 do &lt; 1/100) Rijetko (1/10 000 do &lt; 1/1000) Vrlo rijetko ( &lt; 1/10 000)
Uncommon (1/1,000 to &lt; 1/100) Rare (1/10,000 to &lt; 1/1,000) Very rare ( &lt; 1/10,000)
Manje često (1/1000 i &lt; 1/100) Rijetko (1/10 000 i &lt; 1/1000) Vrlo rijetko ( &lt; 1/10 000)
Uncommon (1/1000, &lt; 1/100)
Manje često (1/1000, &lt; 1/100)
Uncommon ARs (≥1/1,000 to &lt; 1/100)
Manje česte nuspojave (1/1000 i &lt; 1/100)
Uncommon ARs (≥1/1000 to &lt; 1/100)
Manje česte nuspojave (1/1000 i &lt; 1/100)
Uncommon ARs (1/1,000 to &lt; 1/100)
Manje česte nuspojave (1/1000 i &lt; 1/100)
uncommon ≥ 1/1,000 to &lt; 1/100
manje često ≥ 1/1000 i &lt; 1/100
Uncommon ≥ 1/1,000 to &lt; 1/100 Rare ≥ 1/10,000 to &lt; 1/1,000 Very rare &lt; 1/10,000
često ≥ 1/100 i &lt; 1/10 manje često ≥ 1/1000 i &lt; 1/100 rijetko ≥ 1/10 000 i &lt; 1/1000 vrlo rijetko &lt; 1/10 000
Uncommon 1/1,000 to &lt; 1/100 Rare &gt; 1/10,000 to &lt; 1/1000
Često  1/100 i &lt; 1/10 Manje često  1/1000 i &lt; 1/100 Rijetko  1/10 000 i &lt; 1/1000
Uncommon: (≥1/1,000 to &lt; 1/100) Rare: (≥1/10,000 to &lt; 1/1,000)
Često: (≥1/100 do &lt; 1/10) Manje često: (≥1/1000 do &lt; 1/100) Rijetko: (≥1/10 000 do &lt; 1/1000)
Uncommon: (≥1/1,000 to &lt; 1/100) Rare: (≥1/10,000 to &lt; 1/1,000)
Često: ( 1/100 do &lt; 1/10) Manje često: ( 1/1000 do &lt; 1/100) Rijetko: ( 1/10 000 do &lt; 1/1000)
Uncommon: anaemia, mild thrombocytopenia (platelets &lt; 100 G/l)
Manje često: anemija, blaga trombocitopenija (trombociti &lt; 100 g/l).
Uncommon: anaemia, mild thrombocytopenia (platelets &lt; 100 G/L)
Manje često: anemija, blaga trombocitopenija (trombociti &lt; 100 g/l).
Uncommon: Vaccination-site erythema, induration/swelling &gt; 7.0 cm; crying
Manje često: eritem na mjestu primjene cjepiva ili otvrdnuće/oteklina &gt; 7,0 cm; plakanje
Uncommon: ≥ 1/1,000 to &lt; 1/100 Rare: ≥ 1/10,000 to &lt; 1/1,000 Very rare: &lt; 1/10,000
Manje često: ≥ 1/1, 000, &lt; 1/100 Rijetko: ≥ 1/10, 000 do &lt; 1/1, 000 Vrlo rijetko: &lt; 1/10, 000
Uncommon: ≥ 1/1,000 to &lt; 1/100 Rare: ≥ 1/10,000 to &lt; 1/1,000 Very rare: &lt; 1/10,000
Manje često: ≥ 1/1000, &lt; 1/100 Rijetko: ≥ 1/10 000 do &lt; 1/1000 Vrlo rijetko: &lt; 1/10 000
Uncommon: ≥ 1/1,000 to &lt; 1/100 Very rare: &lt; 1/10,000
Manje često:≥ 1/1000 i &lt; 1/100 Vrlo rijetko: &lt; 1/10 000
Uncommon: 1/1,000 to &lt; 1/100 Rare: 1/10,000 to &lt; 1/1,000
Često: ≥1/100 do &lt; 1/10 Manje često: ≥1/1000 do &lt; 1/100 Rijetko: ≥1/10 000 do &lt; 1/1000
Uncommonly ( &gt; 0.1% to &lt; 1%), lack of expected efficacy has been reported in dogs (in the majority of reports a lack of reduction in testicle size was reported and/or a bitch was mated).
Rijetko ( &gt; 0.1% do &lt; 1% ) je prijavljena sumnja na izostanak djelotvornosti u pasa (za većinu slučajeva prijavljen je manja redukcija obima testisa i/ili su kuje već sparene).
Under physiological conditions, ivabradine is rapidly released from tablets and is highly water-soluble ( &gt; 10 mg/ml).
U fiziološkim se uvjetima ivabradin brzo oslobađa iz tableta te je vrlo topljiv u vodi ( &gt; 10 mg/ml).
Underweight patients (body mass index &lt; 18.5 kg/m2)
Pothranjeni bolesnici (indeks tjelesne mase &lt; 18,5 kg/m2)
Undesirable effects possibly related to filgrastim therapy and typically occurring in &lt; 2 % of SCN patients were injection site reaction, headache, hepatomegaly, arthralgia, alopecia, osteoporosis and rash.
Nuspojave koje su možda bile povezane s primjenom filgrastima, obično zabilježene u &lt; 2 % bolesnika s teškom kroničnom neutropenijom, su reakcije na mjestu injekcije, glavobolja, hepatomegalija, artralgija, alopecija, osteoporoza i osip.
Undesirable effects possibly related to filgrastim therapy and typically occurring in &lt; 2% of SCN patients were injection site reaction, headache, hepatomegaly, arthralgia, alopecia, osteoporosis, and rash.
Neželjeni učinci za koje postoji mogućnost da su bili povezani s primjenom filgrastima i koji su se obično javili u &lt; 2% bolesnika s teškom kroničnom neutropenijom, bile su reakcije na mjestu injekcije, glavobolja, hepatomegalija, artralgija, alopecija, osteoporoza i osip.